Nephrogenic Systemic Fibrosis in Patients with Advanced Renal Dysfunction Following Gadolinium-based Contrast Agents.

ABSTRACT: Background The risk of nephrogenic systemic fibrosis (NSF) following administration of contemporary gadolinium-based contrast agents (GBCAs) in patients with advanced chronic kidney disease (CKD) or end-stage renal disease (ESRD) is thought to be low; however, existing reports have involved relatively few participants compared with the number of patients who might benefit from contrast-enhanced MRI in the United States. Purpose To estimate the risk of NSF with contemporary GBCAs in real-world practice in patients with advanced CKD or ESRD. Materials and Methods Adult patients with preexisting diagnoses of stage 4 or 5 CKD or ESRD who received GBCAs between January 2010 and January 2025 were identified retrospectively from the TriNetX U.S. Network. Propensity score matching (PSM) with a con

SUBMITTER: Mallepally A 

PROVIDER: S-EPMC12710783 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature